QIAGEN artus HBV QS-RGQ与Roche CAP/CTM HBV定量检测在慢性乙肝患者血清中的比较
该研究比较了artus HBV QS-RGQ与CAP/CTM v2.0两种HBV DNA定量检测方法在508份慢性乙肝患者血清中的性能。结果显示QS-RGQ的检测率和病毒载量显著低于CAP/CTM v2.0,但精密度良好,线性范围宽,检测下限为2.95 IU/mL,提示样本类型和定量值的临床相关性需考虑。
要点
- QS-RGQ检测率与病毒载量显著低于CAP/CTM v2.0,定性一致性kappa为0.79。
- QS-RGQ精密度良好,总不精密度≤1.4%,线性范围31.6至1.0×10⁷ IU/mL。
- 使用血清样本可能影响QS-RGQ性能,推荐血浆但需结合样本类型评估临床适用性。
核心结论
- artus HBV QS-RGQ检测性能良好,但检测率和病毒载量显著低于CAP/CTM v2.0。
研究设计与样本
- 比较性评估,纳入508份慢性乙肝患者临床血清样本。
- 使用WHO标准97/750和临床样本评估QS-RGQ的精密度、线性及检测下限。
主要发现
- QS-RGQ检测率52.8%显著低于CAP/CTM v2.0的60.6%。
- QS-RGQ病毒载量3.55±1.77 IU/mL显著低于CAP/CTM v2.0的4.18±1.89 IU/mL(P<0.0001)。
- 定性结果kappa系数0.79(95%CI 0.74-0.85)。
- Bland-Altman分析平均差异(QS-RGQ减CAP/CTM v2.0)为-0.63 log₁₀ IU/mL(95%一致性限-1.48至0.22)。
关键数值与推荐
- QS-RGQ在2,000 IU/mL时重复性和总不精密度分别为1.0%和1.1%,在20,000 IU/mL时分别为0.7%和1.4%。
- QS-RGQ线性范围31.6至1.0×10⁷ IU/mL,检测下限2.95 IU/mL。
临床怎么用
- QS-RGQ可用于HBV DNA定量,但需注意其检测率和病毒载量低于CAP/CTM v2.0。
- 该试剂推荐使用血浆,但本研究使用血清,临床应用中应考虑样本类型和定量值的临床相关性。
局限性
- 回顾性研究设计,使用储存血清而非推荐血浆样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B virus DNA quantification is essential for managing chronic hepatitis B (CHB). We compared the performance of artus HBV QS-RGQ (QIAGEN GmbH, Germany) and CAP/CTM v2.0 HBV assays (Roche Molecular Diagnostics, USA) in CHB patients. METHODS: A comparative evaluation between two assays was performed with 508 clinical serum samples. Precision, linearity, and the limit of detection (LOD) of QS-RGQ assay was evaluated by using the WHO standard 97/750 and clinical samples. RESULTS: Detection rates and viral loads as determined QS-RGQ assay were significantly lower than those from the CAP/CTM v2.0 assay (52.8% vs 60.6%; 3.55±1.77 IU/mL vs 4.18±1.89 IU/mL, P<0.0001). The kappa coefficient between qualitative results was 0.79 (95% confidence interval, 0.74 to 0.85). Bland-Altman plot found a mean difference of (QS-RGQ - CAP/CTM v2.0)=-0.63 log₁₀ IU/mL (95% limit of agreement, -1.48 to 0.22). Repeatability and total imprecision (% CV) of the QS-RGQ assay were 1.0% and 1.1% at 2,000 IU/mL, and 0.7% and 1.4% at 20,000 IU/mL, respectively. Linearity of this assay ranged from 31.6 to 1.0±10⁷ IU/mL, and the LOD was 2.95 IU/mL. CONCLUSIONS: The artus HBV QS-RGQ assay showed good performance but significantly decreased detection rate and viral load compared with CAP/CTM v2.0 assays. This assay recommends using plasma; however, we used stored serum because of the retrospective study design. Usually HBV DNA quantification is performed in plasma or serum, but sample type and clinical relevance of quantitative values should be considered when determining the clinical application of this reagent.
引用
- Han MS, Park Y, Nah H, et al. Comparison of the QIAGEN artus HBV QS-RGQ Assay With the Roche COBAS AmpliPrep/COBAS TaqMan HBV Assay for Quantifying Viral DNA in Sera of Chronic Hepatitis B Patients. Ann Lab Med. 2017. PMID: 28224771. doi:10.3343/alm.2017.37.3.248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。